Skip to main content
. 2022 Mar 8;12(4):e2542. doi: 10.1002/brb3.2542

FIGURE 6.

FIGURE 6

Forest of number of patients with ≥50% reduction from baseline in mean monthly migraine days in Eptinezumab group